Celularity (CELU) Non-Current Assets (2018 - 2025)
Celularity (CELU) posted quarterly Non-Current Assets of -$12.0 million for Q4 2025, down 110.69% year-over-year from $112.1 million in Q4 2024, and down 111.56% quarter-over-quarter from $103.6 million in Q3 2025.
Celularity (CELU) Non-Current Assets (2018 - 2025) Analysis & Trends
Celularity (CELU) has reported Non-Current Assets for 8 consecutive years, with -$12.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets fell 110.69% year-over-year to -$12.0 million; the TTM figure through Dec 2025 stood at $301.5 million (down 35.19% YoY), while the FY2025 annual figure was -$12.0 million, down 110.69% from the prior year.
- Non-Current Assets eased to -$12.0 million in Q4 2025 per CELU's latest filing, from $103.6 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $374.0 million in Q3 2022 and bottomed at -$12.0 million in Q4 2025.
- Historically, Non-Current Assets has averaged $209.2 million across 5 years, with a median of $134.5 million in 2021.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 175.7% — and 2025, when it slumped 110.69%.
- Celularity's Non-Current Assets stood at $355.0 million in 2021, then advanced by 3.53% to $367.6 million in 2022, then slumped by 66.24% to $124.1 million in 2023, then slipped by 9.65% to $112.1 million in 2024, then plunged by 110.69% to -$12.0 million in 2025.
- Business Quant data shows CELU's Non-Current Assets at -$12.0 million in Q4 2025, $103.6 million in Q3 2025, and $103.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 18.06 Bn |
| 10 | Celularity | 21.75 Mn | 15.58 Mn | -3.27 Mn | -11.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.98 Mn |
| Sep 30, 2025 | 103.64 Mn |
| Jun 30, 2025 | 103.02 Mn |
| Mar 31, 2025 | 106.80 Mn |
| Dec 31, 2024 | 112.12 Mn |
| Sep 30, 2024 | 114.34 Mn |
| Jun 30, 2024 | 117.76 Mn |
| Mar 31, 2024 | 120.96 Mn |
| Dec 31, 2023 | 124.10 Mn |
| Sep 30, 2023 | 140.69 Mn |
| Jun 30, 2023 | 228.38 Mn |
| Mar 31, 2023 | 337.41 Mn |
| Dec 31, 2022 | 367.56 Mn |
| Sep 30, 2022 | 374.02 Mn |
| Jun 30, 2022 | 353.88 Mn |
| Mar 31, 2022 | 358.46 Mn |
| Dec 31, 2021 | 355.03 Mn |
| Sep 30, 2021 | 357.01 Mn |
| Jun 30, 2021 | 128.36 Mn |
| Mar 31, 2021 | 291.83 Mn |